Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
Shannon Neville WestinMarilyne LabrieJennifer K LittonAurora S BlucherYong FangChristopher P VellanoJoseph R MarszalekNingping FengXiaoYan MaAllison L CreasonBryan FellmanYing YuanSanghoon LeeTae-Beom KimJinsong LiuAnca Chelariu-RaicuTsun Hsuan ChenNashwa KabilPamela T SolimanMichael FrumovitzKatheleen M SchmelerAmir A JazaeriKaren H LuRashmi K MurthyLarissa A MeyerCharlotte C SunAnil K SoodRobert L ColemanGordon B MillsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The combination of olaparib and capivasertib is associated to no serious adverse events and demonstrates durable activity in ovarian, endometrial, and breast cancers, with promising responses in endometrial cancer. Importantly, tumor samples acquired pre- and on-therapy can help predict patient benefit.